Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-088-9 | CAS number: 3001-98-7
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study planned
- Justification for type of information:
- TESTING PROPOSAL ON VERTEBRATE ANIMALS
[Please provide information for all of the points below. The information should be specific to the endpoint for which testing is proposed. Note that for testing proposals addressing testing on vertebrate animals under the REACH Regulation this document will be published on the ECHA website along with the third party consultation on the testing proposal(s).]
NON-CONFIDENTIAL NAME OF SUBSTANCE:
3,9-dimethyl-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane 3,9-dioxide, EC no.: 221-088-9 CAS no.: 3001-98-7
CONSIDERATIONS THAT THE GENERAL ADAPTATION POSSIBILITIES OF ANNEX XI OF THE REACH REGULATION ARE NOT ADEQUATE TO GENERATE THE NECESSARY INFORMATION [please address all points below]:
- No Developmental Toxicity GLP study with the substance is available to the applicant
- No such non-GLP studies are available to the applicant
- No historical human data regarding this endpoint is avalable to the applicant
- (Q)SAR does not provide relevant data to this endpoint
- In vitro methods are not available addressing repeated dose toxicity in vertebrates
- Weight of evidence: no data
- Grouping and read-across
: The applicant considers this developmental toxicity study (first species) is mandatory with the substance, because its molecule structure is free of functional groups causing adverse effects.
- Substance-tailored exposure driven testing: not applicable (0, 50, 300, 1000 mg/kg bw/day)
- Approaches in addition to above: not applicable
- Other reasons: In view of the exisiting OECD 422 test with the substance, the applicant expect not adverse effects for the developmental toxicity study. Such result cannot be proved in any other way than by testing.
The specific result of this study are mandatory for decisions on the necessarity for testing in vertebrates of further higher tier endpoints (devtox second species, reprotox, endokrine).
Data source
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Test material
- Reference substance name:
- 3,9-dimethyl-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane 3,9-dioxide
- EC Number:
- 221-088-9
- EC Name:
- 3,9-dimethyl-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane 3,9-dioxide
- Cas Number:
- 3001-98-7
- Molecular formula:
- C7H14O6P2
- IUPAC Name:
- 3,9-dimethyl-2,4,8,10-tetraoxa-3λ⁵,9λ⁵-diphosphaspiro[5.5]undecane-3,9-dione
- Test material form:
- solid: particulate/powder
- Details on test material:
- AFLAMMIT® PCO 962
Constituent 1
Test animals
- Species:
- rat
Results and discussion
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
